1. Home
  2. ACHV vs UNCY Comparison

ACHV vs UNCY Comparison

Compare ACHV & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Achieve Life Sciences Inc.

ACHV

Achieve Life Sciences Inc.

HOLD

Current Price

$4.56

Market Cap

172.0M

Sector

Health Care

ML Signal

HOLD

Logo Unicycive Therapeutics Inc.

UNCY

Unicycive Therapeutics Inc.

HOLD

Current Price

$8.09

Market Cap

145.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACHV
UNCY
Founded
N/A
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
172.0M
145.3M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
ACHV
UNCY
Price
$4.56
$8.09
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
3
Target Price
$14.67
$25.67
AVG Volume (30 Days)
1.6M
501.9K
Earning Date
05-11-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$675,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$582.86
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.00
$0.47
52 Week High
$6.03
$8.05

Technical Indicators

Market Signals
Indicator
ACHV
UNCY
Relative Strength Index (RSI) 60.45 68.18
Support Level $4.04 $5.95
Resistance Level $5.13 N/A
Average True Range (ATR) 0.42 0.39
MACD 0.04 0.09
Stochastic Oscillator 44.16 86.61

Price Performance

Historical Comparison
ACHV
UNCY

About ACHV Achieve Life Sciences Inc.

Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.

About UNCY Unicycive Therapeutics Inc.

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.

Share on Social Networks: